Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature

Rajul Kothari, Peter A Argenta, Jeffrey Fowler, Jori Carter, William Shimp

Research output: Contribution to journalArticle

8 Scopus citations


Hormonal therapy for adjuvant treatment of ovarian cancer may provide a low toxicity option in some patients with refractory disease. A 53 year-old patient with stage IIIC papillary serous ovarian cancer previously treated with multiple chemotherapy regimens with platinum-resistant disease was treated with antiestrogen therapy for 28 months before requiring reinstitution of cytotoxic chemotherapy. Hormonal therapy may be effective in a subset of epithelial ovarian cancer patients with endocrine sensitivity and should be considered in the treatment of platinum-resistant patients.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalArchive of Oncology
Issue number1-2
StatePublished - Jul 1 2010



  • Antineoplastic Agents
  • Aromatase
  • Hormonal
  • Ovarian Neoplasms
  • Selective Estrogen Receptor Modulators
  • Tamoxifen

Cite this